COVID Variant – BiotechReality – Information Intelligence System for Biopharma

A new COVID variant named JN.1 has been identified that can spread rapidly compared to the other variants. It is a sub-variant of the Omicron variant which the WHO considered a "variant of interest" because it is rapidly spreading. CDC says that the upcoming holidays and ongoing winter may cause the condition to worsen. This variant is now rapidly spreading in countries mainly the UK, India and more. CDC says that there is no current risk to the health from the spreading variants. They also suggest for an updated COVID jab for increased protection. Also Read| Nobel Prize 2023 in Medicine for the scientists behind mRNA COVID-19 vaccines JN.1’s continued growth suggests that the variant is either more transmissible or better at evading our immune systems than other circulating variants. It is too early to know whether or to what extent JN.1 will cause an increase in infections or hospitalizations. CDC The rise in the spread suggests that the sub-variant may have the ability to evade the immune system. Also Read| Highly mutated COVID-19 strain found in new countries CDC also stated that the COVID spread usually increases during the festive as well as the winter season every year, without considering the sub-variants. They also suggest that the existing vaccination, tests, and treatments are still effective against the JN.1. Every people especially the people in the high-risk category should take effective actions and tests to prevent the spread of the JN.1. Last Updated

Tag: COVID Variant

JN.1 New COVID-19 variant: Spreading rapidly

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment